Discussion
PTC Therapeutics has been selected as the winning bidder to acquire ST-920 (isaralgagene civaparvovec), a one-time gene therapy candidate for Fabry disease, from the therapy’s original developer, Sangamo Therapeutics, in a competitive bankruptcy auction. PTC said it will leverage existing regulatory and commercial infrastructure, and expects to…